SCHEMBL25257598

SCHEMBL25257598

CC(C)(C)OC(=O)CCN(CCCC(=O)OCc1ccccc1)C(=O)OCCl

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 1/20 0.44
PAX8 Q06710 1/20 0.44
ALOX5 P09917 1/20 0.41
L3MBTL1 Q9Y468 5/20 0.40
LMNA P02545 1/20 0.39
SYK P43405 1/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPK1 P28482 1/20 0.38
CCKBR P32239 1/20 0.38
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25245639 0.91 CCR6 (0.41) CCR6PAX8ALOX5L3MBTL1LMNA
SCHEMBL25230901 0.89 CCR6 (0.45) CCR6PAX8ALOX5L3MBTL1SYK
SCHEMBL25209279 0.89 L3MBTL1 (0.40) CCR6PAX8L3MBTL1LMNASYK
SCHEMBL25229018 0.87 CCR6 (0.41) CCR6PAX8L3MBTL1LMNASYK
SCHEMBL20089220 0.86 L3MBTL1 (0.46) CCR6PAX8L3MBTL1LMNASYK
SCHEMBL25277118 0.86 CCR6 (0.41) CCR6PAX8L3MBTL1SYKALDH1A1
SCHEMBL25221576 0.86 L3MBTL1 (0.48) CCR6PAX8L3MBTL1LMNASYK
SCHEMBL23685489 0.84 CCR6 (0.53) CCR6PAX8ALOX5L3MBTL1LMNA
SCHEMBL22899929 0.84 CCR6 (0.53) CCR6PAX8ALOX5L3MBTL1LMNA
SCHEMBL6338766 0.84 CCR6 (0.50) CCR6PAX8ALOX5L3MBTL1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4566608-A2 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION Gilead Sciences, Inc. (US) 2025-06-11 EP disclosed
US-20250179102-A1 THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. 2025-06-05 US disclosed
EP-4440702-B1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES INC (US) 2025-05-21 EP disclosed
EP-4445900-B1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES INC (US) 2025-05-21 EP disclosed
US-12187753-B2 Therapeutics compounds for HIV virus infection GILEAD SCIENCES, INC. (US) 2025-01-07 US disclosed
EP-4445900-A2 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION Gilead Sciences, Inc. (US) 2024-10-16 EP disclosed
EP-4440702-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2024-10-09 EP disclosed
US-20240132527-A1 THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. 2024-04-25 US disclosed
US-11787825-B2 Therapeutic compounds for HIV virus infection GILEAD SCIENCES, INC. (US) 2023-10-17 US disclosed
US-20230203069-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. 2023-06-29 US disclosed
WO-2023102239-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2023-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179102-A1 THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION CD4, HAVCR2, MAVS CCR6 33/4885PAX8 4710/4885ALOX5 565/4885
US-11787825-B2 Therapeutic compounds for HIV virus infection HAVCR2, MAVS, CD4 CCR6 39/4885PAX8 4627/4885ALOX5 674/4885
US-12187753-B2 Therapeutics compounds for HIV virus infection CD4, HAVCR2, MAVS CCR6 33/4885PAX8 4710/4885ALOX5 565/4885
US-20230203069-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION HAVCR2, MAVS, CD4 CCR6 39/4885PAX8 4627/4885ALOX5 674/4885
US-20240132527-A1 THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION CD4, HAVCR2, MAVS CCR6 33/4885PAX8 4710/4885ALOX5 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.